Zug (ots) - AmVac AG has a new executive officer on board - Dr.
Wolfgang Schmidt agreed to join the company in early December to lead
its operational business.
Dr. Wolfgang Schmidt is a graduated chemist who began his career
with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints
in pharmaceutical research, he directed the site-management Frankfurt
department in the lead generation research segment. In this position
he was also at the helm of the business plan competition, Science 4
Life. Next, he joined Sanofi-Aventis in Frankfurt, where he was put
in charge of the management of research contracts. At AmVac, Dr.
Schmidt will join forces with Mrs. Melinda-Kinga Karpati, the CEO of
AmVac, to coordinate and direct the company's operational business
activities as well as the integration of the new technologies
acquired from the Max-Planck-Institute for Biochemistry and from the
Helmholtz Center for Infection Research.
About AmVac AG
AmVac AG is company engaged in the biological/pharmaceutical
market headquartered in Switzerland, and focuses on the market for
This press release constitutes neither an offer to sell nor a
solicitation to buy securities of AmVac AG in any jurisdiction. This
press release must not being issued in the United States of America
and must not be distributed to United States persons or publications
with a general circulation in the United States.
ots Originaltext: AmVac AG